Quanterix Corporation (QTRX) Earnings Call Transcripts

Quanterix Corporation's Latest Earnings Call - June 9, 2026

In the Q2 2026 earnings call, Quanterix Corporation (QTRX:US) reported a revenue of $25.4 million, which was in line with expectations but showed a 10% decline year-over-year. The company reaffirmed its guidance for the fiscal year, targeting revenue growth in the second half driven by upcoming FDA approvals and clinical utility studies. Management highlighted significant catalysts, including the anticipated FDA approval of their LucentAD Complete test and ongoing reimbursement discussions, which could positively impact future earnings.

Reported metrics

Guidance from management

Management reaffirmed their revenue guidance for the fiscal year, indicating confidence in achieving growth in the second half driven by FDA approvals and clinical utility studies.

What management said

Yes. We submitted our 510(k) in January. We've had ongoing conversations with the FDA. While we can't predict what the FDA is going to do, we have all signs that we're going to get FDA approval in the second half of this year. And that time line is right on track. A good sign is the FDA continuing to ask us really solid questions and us following up on those questions. So we feel good about -- and that is a really bi...

Growth is one. I think another key metric. And we're working really closely with Tempus is we're being strategic on those health systems that we target. Health systems that see a lot of Alzheimer's. Health systems that we have access to. Health systems, like I said, that have a solid EMR partnership. And those are the ones that we started to go to. We kicked this off at the end of Q1. And throughout the year, I'm sur...

What analysts pressed on

Analysts expressed concerns over the broader market conditions impacting revenue and the pace of recovery in instrumentation sales. There were questions regarding how management plans to navigate these challenges while achieving growth targets.

Main topics on the call

• FDA Approval Timeline — Management expressed confidence in receiving FDA approval for the LucentAD Complete test in the second half of 2026, stating, "all signs are headed in the right direction." This approval is critical for expanding their d...
• Clinical Utility Studies — Three clinical utility studies are expected to read out in the second half of the year, which management believes will aid in reimbursement discussions with payers. These studies are being conducted with reputable partne...
• Revenue Guidance Maintenance — Management maintained their revenue guidance for the fiscal year, indicating confidence in achieving growth in the second half despite a challenging first quarter. They stated, "we will hit cash breakeven in the second h...
• Market Conditions and Strategy — Management acknowledged tough end market conditions but emphasized a proactive approach to capture growth opportunities. They are enhancing their commercial organization and focusing on lead generation to drive new busin...

Read the full Quanterix Corporation transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 49 Quanterix Corporation earnings call transcripts on record, spanning January 16, 2020 to August 10, 2026. Based on this history, Quanterix Corporation reports quarterly. The most recent call on file is dated August 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

QTRX

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

49

First call

January 16, 2020

Most recent

August 10, 2026

Reporting cadence

quarterly